News Conference News AHA 2018 Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis Caitlin E. Cox November 13, 2018
News Daily News FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now Michael O'Riordan November 01, 2018
News Features The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine Shelley Wood October 22, 2018
News Conference News ESC 2018 MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis Todd Neale August 26, 2018
News Daily News SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function Todd Neale July 02, 2018
News Conference News EAS 2018 ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran Yael L. Maxwell May 14, 2018
News Conference News ACC 2018 Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS Michael O'Riordan March 12, 2018
News Conference News ACC 2018 ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins Shelley Wood March 10, 2018
News Features Mercury Rising: As Doctors’ Groups Face Off Over BP Guidelines, Will Patients Fall Through the Cracks? L.A. McKeown February 26, 2018
News Daily News Roughly Half of Obese Patients Who Have Bariatric Surgery Are Off Type 2 Diabetes Meds at 6 Years Michael O'Riordan February 19, 2018
News Daily News Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers Yael L. Maxwell January 24, 2018
News Daily News It’s Official: Evolocumab Gains Claim for CVD Event Reduction Michael O'Riordan December 04, 2017
News Conference News AHA 2017 CANTOS: Big Drop in CVD Events Among Canakinumab Responders Michael O'Riordan November 13, 2017
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017
News Daily News Costs Up, Usage Down: Hospitals Curtailed Use of CV Meds When Prices Soared Todd Neale August 15, 2017
News Daily News ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year Yael L. Maxwell August 07, 2017
News Conference News EAS 2017 Perceived Financial Barriers to Healthcare Worsen Cardiovascular Outcomes Even in Countries With Universal Medical Coverage Yael L. Maxwell April 27, 2017
News Conference News ACC 2017 ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s Yael L. Maxwell March 17, 2017
News Daily News High-Sensitivity Troponin Assays May Help With Response to Statins and Other Meds Todd Neale December 19, 2016
News Conference News AHA 2016 No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION Shelley Wood November 13, 2016